Demographic and clinical characteristics of patients who underwent allogeneic HSCT for AML or MDS (N = 350)
| Characteristic . | Overall (N = 350) . | SIRPα mismatched (n = 136) . | SIRPα matched (n = 214) . | P . |
|---|---|---|---|---|
| Age at HSCT, y | .6 | |||
| ≤40 | 68 (19) | 25 (18) | 43 (20) | |
| 41-50 | 61 (17) | 20 (15) | 41 (19) | |
| 51-60 | 124 (35) | 53 (39) | 71 (33) | |
| >60 | 97 (28) | 38 (28) | 59 (28) | |
| Diagnosis | .8 | |||
| Primary AML | 249 (71) | 96 (71) | 153 (71) | |
| MDS | 101 (29) | 40 (29) | 61 (29) | |
| ELN risk status for AML* | .6 | |||
| Favorable | 43 (17) | 16 (17) | 27 (18) | |
| Intermediate | 133 (53) | 56 (57) | 78 (51) | |
| Adverse | 72 (29) | 25 (26) | 47 (31) | |
| Missing | 1 (0.4) | 0 (0) | 1 (1) | |
| IPSS for MDS | .4 | |||
| Good | 30 (30) | 14 (35) | 16 (26) | |
| Intermediate† | 17 (17) | 8 (20) | 9 (15) | |
| Bad | 54 (54) | 18 (45) | 36 (59) | |
| Disease status at HSCT | .2 | |||
| Remission | 162 (46) | 69 (51) | 93 (43) | |
| Not in remission | 188 (54) | 67 (49) | 121 (57) | |
| HSCT-CI | .4 | |||
| <3 | 177 (51) | 65 (48) | 112 (52) | |
| ≥3 | 173 (49) | 71 (52) | 102 (48) | |
| Conditioning intensity | .4 | |||
| Myeloablative | 317 (91) | 121 (89) | 196 (92) | |
| Nonmyeloablative | 33 (9) | 15 (11) | 18 (8) | |
| GVHD prophylaxis | .7 | |||
| Tacrolimus/methotrexate | 347 (99) | 135 (99) | 212 (99) | |
| Tacrolimus/MMF | 3 (1) | 1 (1) | 2 (1) | |
| Donor/recipient sex | .7 | |||
| Male/male | 107 (31) | 38 (28) | 69 (32) | |
| Female/male | 100 (29) | 38 (28) | 62 (29) | |
| Female/female | 70 (20) | 28 (21) | 42 (20) | |
| Male/female | 73 (21) | 32 (23) | 41 (19) | |
| Donor/recipient CMV status | .8 | |||
| NR/NR | 26 (7) | 10 (7) | 16 (7) | |
| R/NR | 12 (3) | 6 (4) | 6 (3) | |
| R/R | 194 (55) | 72 (53) | 122 (57) | |
| NR/R | 117 (33) | 48 (35) | 69 (32) | |
| Missing | 1 (0.3) | 0 (0) | 1 (0.5) | |
| Donor/recipient ABO | .3 | |||
| Matched | 209 (60) | 82 (60) | 127 (59) | |
| Minor mismatch | 64 (18) | 25 (18) | 39 (18) | |
| Major mismatch | 67 (19) | 28 (21) | 39 (18) | |
| Bidirectional mismatch | 10 (3) | 1 (1) | 9 (4) |
| Characteristic . | Overall (N = 350) . | SIRPα mismatched (n = 136) . | SIRPα matched (n = 214) . | P . |
|---|---|---|---|---|
| Age at HSCT, y | .6 | |||
| ≤40 | 68 (19) | 25 (18) | 43 (20) | |
| 41-50 | 61 (17) | 20 (15) | 41 (19) | |
| 51-60 | 124 (35) | 53 (39) | 71 (33) | |
| >60 | 97 (28) | 38 (28) | 59 (28) | |
| Diagnosis | .8 | |||
| Primary AML | 249 (71) | 96 (71) | 153 (71) | |
| MDS | 101 (29) | 40 (29) | 61 (29) | |
| ELN risk status for AML* | .6 | |||
| Favorable | 43 (17) | 16 (17) | 27 (18) | |
| Intermediate | 133 (53) | 56 (57) | 78 (51) | |
| Adverse | 72 (29) | 25 (26) | 47 (31) | |
| Missing | 1 (0.4) | 0 (0) | 1 (1) | |
| IPSS for MDS | .4 | |||
| Good | 30 (30) | 14 (35) | 16 (26) | |
| Intermediate† | 17 (17) | 8 (20) | 9 (15) | |
| Bad | 54 (54) | 18 (45) | 36 (59) | |
| Disease status at HSCT | .2 | |||
| Remission | 162 (46) | 69 (51) | 93 (43) | |
| Not in remission | 188 (54) | 67 (49) | 121 (57) | |
| HSCT-CI | .4 | |||
| <3 | 177 (51) | 65 (48) | 112 (52) | |
| ≥3 | 173 (49) | 71 (52) | 102 (48) | |
| Conditioning intensity | .4 | |||
| Myeloablative | 317 (91) | 121 (89) | 196 (92) | |
| Nonmyeloablative | 33 (9) | 15 (11) | 18 (8) | |
| GVHD prophylaxis | .7 | |||
| Tacrolimus/methotrexate | 347 (99) | 135 (99) | 212 (99) | |
| Tacrolimus/MMF | 3 (1) | 1 (1) | 2 (1) | |
| Donor/recipient sex | .7 | |||
| Male/male | 107 (31) | 38 (28) | 69 (32) | |
| Female/male | 100 (29) | 38 (28) | 62 (29) | |
| Female/female | 70 (20) | 28 (21) | 42 (20) | |
| Male/female | 73 (21) | 32 (23) | 41 (19) | |
| Donor/recipient CMV status | .8 | |||
| NR/NR | 26 (7) | 10 (7) | 16 (7) | |
| R/NR | 12 (3) | 6 (4) | 6 (3) | |
| R/R | 194 (55) | 72 (53) | 122 (57) | |
| NR/R | 117 (33) | 48 (35) | 69 (32) | |
| Missing | 1 (0.3) | 0 (0) | 1 (0.5) | |
| Donor/recipient ABO | .3 | |||
| Matched | 209 (60) | 82 (60) | 127 (59) | |
| Minor mismatch | 64 (18) | 25 (18) | 39 (18) | |
| Major mismatch | 67 (19) | 28 (21) | 39 (18) | |
| Bidirectional mismatch | 10 (3) | 1 (1) | 9 (4) |
Data are n (%), percentages may not add to 100% because of rounding. Mismatched SIRPα included mismatches in either direction (G vs H).
IPSS, International Prognostic Scoring System; MMF, mycophenolate mofetil; NR, nonreactive; R, reactive.
Two hundred and forty-nine patients were in the overall group: 96 for SIRPα matched, 153 for SIRPα mismatched.
The Intermediate group includes categories intermediate 1 and intermediate 2 of the IPSS.